TECHNOLOGY LICENSING OPPORTUNITY: PlagueGuard Antibodies

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

TRIAD - DOE CONTRACTOR

Contract Value

Not provided

Codes & Classification
Solicitation Number

-

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Classification Code

6505

Additional Details
Set Aside

NONE

Place of Performance

Los Alamos, New Mexico, UNITED STATES

SourceSAM
Documents1
Los Alamos National Laboratory (LANL), operating under the TRIAD - DOE CONTRACTOR, has issued a special notice regarding a technology licensing opportunity for "PlagueGuard Antibodies." This initiative centers on the commercialization of high-affinity human antibodies developed by LANL scientists, designed to rapidly detect and potentially treat infections caused by Yersinia pestis—the bacterium responsible for plague. The technology addresses critical challenges in both public health and biodefense, particularly the growing threat of antibiotic-resistant strains and the need for reliable, field-deployable diagnostics. Purpose and Scope: The primary objective of this licensing opportunity is to transition LANL’s patented antibody technology (US Patent No. 11,702,465) into commercial applications. The antibodies are engineered to bind with exceptional sensitivity and specificity to the F1 antigen, a key marker of virulent Y. pestis strains. By targeting two distinct epitopes on the antigen, these antibodies minimize false positives and enhance diagnostic accuracy. Their chemical resilience allows for versatile use in both rapid diagnostic platforms (such as lateral flow assays) and therapeutic modalities, including radioimmunotherapy—an alternative treatment pathway especially relevant in scenarios where conventional antibiotics may fail. Intended Outcomes: LANL seeks to enable commercial partners to leverage these antibodies for a range of market applications, including: - Infectious disease diagnostics for public health agencies and clinical laboratories - Biodefense and national security solutions for government and military stakeholders - Pharmaceutical and biotech development, particularly in the area of targeted therapeutics and radiopharmaceuticals - Veterinary and agricultural biosafety, addressing zoonotic and environmental risks Key Requirements and Deliverables: Interested parties are invited to pursue licensing agreements—either exclusive or non-exclusive—to access the patented technology and associated know-how. The deliverables include rights to utilize, manufacture, and further develop the PlagueGuard antibodies for commercial products and services. LANL’s technology transfer program is designed to facilitate the movement of laboratory innovations into the marketplace, supporting both established and start-up companies. Relevant Details: - Contracting Entity: TRIAD - DOE CONTRACTOR (Federal Office) - Location: Los Alamos, New Mexico, United States - NAICS Code: 325414 (Biological Product [except Diagnostic] Manufacturing, 2022) - Product Service Code: 6505 - Set-Aside: None (open to all qualified entities) - Contact Information: - Primary: Mike Erickson ([email protected]) - Secondary: Lindsay Augustyn ([email protected]) - Notice Status: Active - Response Deadline: October 10, 2025 - Notice URL: https://sam.gov/opp/6d9a4de7d700440fb535cafede950093/view Special Considerations: This notice is not a solicitation for external development services; rather, it is an invitation to license and commercialize existing LANL technology. The laboratory’s licensing program offers flexibility in agreement structures and supports the integration of patented inventions into commercial portfolios. Interested parties are encouraged to review additional information and initiate discussions via the provided contact channels. For further details on LANL’s technology transfer process and available capabilities, visit: - https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology - https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search Summary: This opportunity represents a significant advancement in the detection and treatment of plague, with broad implications for public health, biodefense, and pharmaceutical innovation. Contractors and companies with expertise in biological product manufacturing, diagnostics, therapeutics, or related fields are encouraged to evaluate the alignment of this technology with their strategic objectives and to engage with LANL’s licensing team for further information.